Arbutus Biopharma Corp
Status: Publicly traded
Direct answer
Arbutus Biopharma Corp is publicly traded on NASDAQ under the ticker ABUS.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1...
Can you invest in Arbutus Biopharma Corp?
Yes. Arbutus Biopharma Corp trades publicly on NASDAQ as ABUS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Arbutus Biopharma Corp
Detailed equity research is provided by MarketSnap.